Triflusal Triflusal Triflusal is a platelet aggregation inhibitor that was discovered and developed in the Uriach Laboratories, and commercialised in Spain since 1981. Currently, it is available in 25 countries in Europe, Asia, Africa and America. It is a drug of the salicylate family but it is not a derivative of acetylsalicylic acid (ASA). Trade names include Disgren, Grendis, Aflen and Triflux. Triflusal is a selective platelet antiaggregant through; Triflusal is indicated for; In the 2008 guidelines for stroke management from the European Stroke Organization, triflusal was for the first time recommended as lone therapy, as an alternative to acetylsalicylic acid
Trademark on colour, smell, or sound (like jingles). Trademarks which are considered offensive are often rejected according to a nation's trademark law. The term "trademark" is also used informally to refer to any distinguishing attribute by which an individual is readily identified, such as the well-known characteristics of celebrities. When a trademark is used in relation to services rather than products, it may sometimes be called a service mark, particularly in the United States. The essential function of a trademark is to exclusively identify the commercial source or origin of products or services, so a trademark, properly called, "indicates source" or